文献速递帕金森病与运动障碍

帕金森病药物治疗的启动时机、原因与方式

Initiation of pharmacological therapy in Parkinson's disease: when, why, and how.
PubMed 文献 · Lancet Neurol · 2020-03-12

本文综述帕金森病药物治疗启动的争议。早期启动多巴胺能治疗虽无疾病修饰作用但可减少残疾;PD MED和LEAP研究缓解了对左旋多巴早期使用致运动并发症的担忧,LEAP还显示早期改善生活质量的潜力。当前证据支持左旋多巴作为多数患者初始对症治疗,低剂量起始并滴定至治疗阈值。

要点

  • 早期多巴胺能治疗无疾病修饰作用,但可减少残疾。
  • 左旋多巴早期使用致运动并发症的担忧已被PD MED和LEAP研究缓解。
  • 当前证据支持左旋多巴作为多数患者初始对症治疗,低剂量起始滴定。

核心结论

  • 当前证据支持左旋多巴作为多数帕金森病患者的初始对症治疗,以低剂量起始并滴定至治疗阈值。
  • 单胺氧化酶B抑制剂和多巴胺激动剂可保留为疾病后期潜在的辅助治疗。

研究设计与样本

  • 本文为综述,引用PD MED和LEAP研究等证据讨论帕金森病药物治疗启动的时机、原因和方式。

主要发现

  • 早期启动多巴胺能治疗不产生疾病修饰效应,但可减少残疾。
  • PD MED和LEAP研究结果在很大程度上缓解了早期使用左旋多巴致运动并发症的担忧。
  • LEAP研究显示,即使残疾轻微,早期治疗也可能改善生活质量。

临床怎么用

  • 对多数帕金森病患者,可考虑以左旋多巴作为初始对症治疗,低剂量起始并滴定至治疗阈值。
  • 单胺氧化酶B抑制剂和多巴胺激动剂可保留为疾病后期潜在的辅助治疗选择。

局限性

  • 未来需建立有效的疾病修饰治疗,并明确早期启动治疗相比观察等待是否显著改善生活质量。
  • 需确定新型左旋多巴制剂能否延迟运动障碍的发生。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Debate is ongoing regarding when, why, and how to initiate pharmacotherapy for Parkinson's disease. Early initiation of dopaminergic therapies does not convey disease-modifying effects but does reduce disability. Concerns about the development of motor complications arising from the early initiation of levodopa, which led to misconceived levodopa-sparing strategies, have been largely mitigated by the outcomes of the PD MED and Levodopa in Early Parkinson's Disease (LEAP) studies. The LEAP study also showed the potential for early improvement in quality of life, even when disability is negligible. Until more effective methods of providing stable dopamine concentrations are developed, current evidence supports the use of levodopa as initial symptomatic treatment in most patients with Parkinson's disease, starting with low doses and titrating to therapeutic threshold. Monoamine oxidase-B inhibitors and dopamine agonists can be reserved as potential adjunct treatments later in the disease course. Future research will need to establish effective disease-modifying treatments, address whether patients' quality of life is substantially improved with early initiation of treatment rather than a wait and watch strategy, and establish whether new levodopa formulations will delay onset of dyskinesia.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. de Bie RMA, Clarke CE, Espay AJ, et al. Initiation of pharmacological therapy in Parkinson's disease: when, why, and how. Lancet Neurol. 2020. PMID: 32171387. doi:10.1016/S1474-4422(20)30036-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。